1.222SEK-1.77%Mkt Cap: 106.00M SEKP/E: —Last update: 2026-05-13
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which ha…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-9.60
PEG—
P/B3.45
P/S1.84
EV/EBITDA-0.62
EV/Revenue0.97
EPS (TTM)-0.88
EPS (Forward)-0.13
Cash Flow & Leverage
FCF Yield-21.02%
FCF Margin-38.78%
Operating CF-55.22M SEK
CapEx (TTM)—
Net Debt/EBITDA0.58
Net Debt-51.91M SEK
Technical
SMA 501.475 (-17.2%)
SMA 2002.121 (-42.4%)
Beta0.53
S&P 52W Chg24.23%
Avg Vol (30d)208.97K
Avg Vol (10d)364.38K
Technical Indicators
RSI (14)32.7
MACD-0.0844
MACD Signal-0.0670
MACD Hist.-0.0174
BB Upper1.659 SEK
BB Middle1.401 SEK
BB Lower1.143 SEK
BB Width36.89%
ATR (14)0.0939 SEK
Vol Ratio (20d)0.24x
52W Range
1.1701% of range7.880
52W High7.880 SEK
52W Low1.170 SEK
Profitability
Gross Margin-72.94%
EBITDA Margin-155.02%
Profit Margin-191.45%
Oper. Margin-148.46%
ROE-358.13%
ROA-78.13%
Revenue Growth-65.60%
Earnings Growth—
Balance Sheet
Debt/Equity0.98
Current Ratio0.80
Quick Ratio0.80
Book Value/Sh0.3620 SEK
Cash/Share0.9640 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split5:1
Split DateMay 28, 2019
Ownership
Shares Out.84.86M
Float67.50M
Insiders26.18%
Institutions10.61%
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)7.500 SEK
Target Range7.500 SEK – 7.500 SEK
# Analysts1
Company
Market Cap106.00M SEK
Enterprise Value55.62M SEK
Revenue (TTM)57.46M SEK
Gross Profit-41.91M SEK
Net Income (TTM)-110.01M SEK
Revenue/Share0.8580 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees31
Last Price1.222 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—